Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 8/2021

01.08.2021 | Cardio-Oncology (TG Neilan, Section Editor)

Cardiovascular Toxicity of Androgen Deprivation Therapy

verfasst von: Julia Boland, William Choi, Maximillian Lee, Jianqing Lin

Erschienen in: Current Cardiology Reports | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Androgen deprivation therapy (ADT) is the standard of care for the treatment of advanced prostate cancer (PC). ADT, particularly with GnRH agonists, leads to increased risk of cardiovascular disease, including myocardial infarction, hypertension, and stroke. This review discusses the options of ADT, the mechanism of ADT-associated cardiovascular side effects, and potential benefit by using GnRH antagonists.

Recent Findings

GnRH antagonists have relatively less cardiovascular adverse effects compared to GnRH agonists. We highlight on a recently published phase III clinical trial on the oral GnRH antagonist, relugolix, and its comparative benefit to traditional GnRH agonist regarding development of cardiovascular disease.

Summary

Recent data reinforces that GnRH antagonists have a more favorable cardiovascular outcomes compared to GnRH agonists yet maintain a similar efficacy profile. From the data we reviewed, GnRH antagonists may be the preferred method of ADT for PC, but further data with primary cardiovascular outcomes are warranted.
Literatur
1.
2.
Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, et al. Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. J Clin Oncol. 2018;36(32):3251–8.PubMedCrossRef
3.
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet, 2000. 355(9214): p. 1491-8.
4.
Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133(5):537–41.PubMedPubMedCentralCrossRef
5.
Knutsson A, Hsiung S, Celik S, Rattik S, Mattisson IY, Wigren M, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(-/-) mice. Sci Rep. 2016;6:26220.PubMedPubMedCentralCrossRef
6.
• Leong DP, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203(6):1109–16 This prospective study demonstrated that two thirds of men with prostate cancer are at an increased risk of cardiovascular disease.PubMedCrossRef
7.
Collaborators, G.B.D.C.o.D. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016 a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–210.CrossRef
8.
Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.PubMedCrossRef
9.
Waxman J, Man A, Hendry WF, Whitfield HN, Besser GM, Tiptaft RC, et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed). 1985;291(6506):1387–8.CrossRef
10.
van Poppel H, Nilsson S. Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology. 2008;71(6):1001–6.PubMedCrossRef
11.
Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991;324(2):93–103.PubMedCrossRef
12.
Sharifi R, Browneller R, Leuprolide Study G. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol. 2002;168(3):1001–4.PubMedCrossRef
13.
Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8.PubMedCrossRef
14.
15.
Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565–73.PubMedCrossRef
16.
•• Margel D, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019;202(6):1199–208 This study showed significant less cardiovascular side effects by using GnRH antagonist comparing to GnRH agonist.PubMedCrossRef
17.
Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4):1305–8.PubMedCrossRef
18.
Kiwata JL, Dorff TB, Schroeder ET, Gross ME, Dieli-Conwright CM. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer Prostatic Dis. 2016;19(4):323–32.PubMedPubMedCentralCrossRef
19.
Yu IC, Lin HY, Sparks JD, Yeh S, Chang C. Androgen receptor roles in insulin resistance and obesity in males: the linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes. 2014;63(10):3180–8.PubMedPubMedCentralCrossRef
20.
Luo C, Pook E, Tang B, Zhang W, Li S, Leineweber K, et al. Androgen inhibits key atherosclerotic processes by directly activating ADTRP transcription. Biochim Biophys Acta Mol basis Dis. 2017;1863(9):2319–32.PubMedCrossRef
21.
Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med. 2010;7(4 Pt 1):1557–64.PubMedCrossRef
22.
Corona G, Rastrelli G, di Pasquale G, Sforza A, Mannucci E, Maggi M. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15(9):1260–71.PubMedCrossRef
23.
Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706–15.PubMedCrossRef
24.
Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.PubMedPubMedCentralCrossRef
25.
Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36.PubMedCrossRef
26.
Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017;35(5):183–91.PubMedCrossRef
27.
• Dearnaley DP, et al. The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: a randomised, open-label, parallel-group phase 2 trial. Eur Urol. 2020;78(2):184–92. This study supports the use of oral GnRH antagonist relugolix in combination with radiation therapy in patients with intermediate and high risk PCa. https://​doi.​org/​10.​1016/​j.​eururo.​2020.​03.​001.PubMedCrossRef
28.
•• Shore ND, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020;382(23):2187–96 This study demonstrated that the oral GnRH antagonist relugolix led to sustained castrate testosterone levels and a decreased risk of MACE compared to injectible LHRH agonist leuprolide.PubMedCrossRef
29.
Margel, D., et al., Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist. Prostate Cancer Prostatic Dis, 2020.
30.
Melloni C, et al. Cardiovascular safety of degarelix versus leuprolide for advanced prostate cancer: the PRONOUNCE trial study design. JACC: CardioOncol. 2020;2(1):70–81.
31.
•• Sternberg CN, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23):2197–206 The findings from this study showed that patients who received enzalutamide with ADT compared to ADT alone had a longer median overall survival. Of note, patients who received enzalutamide had an increased incidence of hypertension and cardiovascular events leading to death.PubMedCrossRef
32.
Di Nunno V, et al. New hormonal agents in patients with nonmetastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety outcomes. Clin Genitourin Cancer. 2019;17(5):e871–7.PubMedCrossRef
33.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–74.PubMedPubMedCentralCrossRef
34.
Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, et al. The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer. 2018;16(3):e645–53.PubMedCrossRef
35.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.PubMedCrossRef
36.
Saltalamacchia G, et al. Renal and cardiovascular toxicities by new systemic treatments for prostate cancer. Cancers (Basel). 2020;12(7).
37.
Bretagne M, Lebrun-Vignes B, Pariente A, Shaffer CM, Malouf GG, Dureau P, et al. Heart failure and atrial tachyarrhythmia on abiraterone: a pharmacovigilance study. Arch Cardiovasc Dis. 2020;113(1):9–21.PubMedCrossRef
Metadaten
Titel
Cardiovascular Toxicity of Androgen Deprivation Therapy
verfasst von
Julia Boland
William Choi
Maximillian Lee
Jianqing Lin
Publikationsdatum
01.08.2021
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 8/2021
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-021-01561-9

Weitere Artikel der Ausgabe 8/2021

Current Cardiology Reports 8/2021 Zur Ausgabe

Cardiac PET, CT, and MRI (P Schoenhagen and P-H Chen, Section Editors)

Anomalous Coronary Arteries: When to Follow-up, Risk Stratify, and Plan Intervention

Nuclear Cardiology (V Dilsizian, Section Editor)

Molecular Imaging Using Cardiac PET/CT: Opportunities to Harmonize Diagnosis and Therapy

Echocardiography (JM Gardin and AH Waller, Section Editors)

Pulse-Cancellation Echocardiography for Clinical Evaluation of Myocardial Scar Burden

Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)

The Riskier Lipid: What Is on the HORIZON for Lipoprotein (a) and Should There Be Lp(a) Screening for All?

Diabetes and Cardiovascular Disease (D Bruemmer, Section Editor)

Weight Management Strategies for the Patient with Diabetes

Structural Heart Disease (RJ Siegel and NC Wunderlich, Section Editors)

Atrioventricular Septal Defects: Pathology, Imaging, and Treatment Options

Neu im Fachgebiet Kardiologie

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise